ReviewSeminars in cancer biology2023
Obesity and renal cell carcinoma: Biological mechanisms and perspectives.
Review in Seminars in cancer biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 34 citations in OpenAlex.
- Ultra-processed food intake and risk of renal cell carcinoma in the NIH-AARP Diet and health study: a prospective cohort analysis.Lancet regional health. Americas · 2026Article
- Renal cell carcinoma: molecular understanding and therapeutic development.Cell death and differentiation · 2026Review
- Review
- Role of miR-34a/KLF4 axis in podocyte injury and obesity-related glomerulopathy with preliminary observations in clear cell renal cell carcinoma.Current urology · 2026Article
- Review
- Body composition and renal cell carcinoma prognosis in elderly patients: a retrospective cohort study.BMC urology · 2026Article
- Association between physical activity patterns and renal cell carcinoma risk: evidence from the UK biobank large-scale prospective cohort.Scientific reports · 2026Article
- Resveratrol Mimics Exercise-Induced Metabolic Stress to Suppress CIP2A and Epithelial-Mesenchymal Transition in 3D Renal Carcinoma Spheroids.Biomedicines · 2026Article
- Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma.Journal for immunotherapy of cancer · 2026Article
- Insights into the mechanisms of drug resistance in renal cell carcinoma: from multi-omics perspective.International journal of surgery (London, England) · 2026Article
- Impact of metabolic syndrome and its components on the tumor aggressiveness of renal cell carcinoma.Medicine · 2026Observational
- Comprehensive analysis of key palmitoylation-modifying enzymes in clear cell renal cell carcinoma: implications for prognosis and therapy.Cancer cell international · 2026Article
- Obesity-driven metabolic reprogramming and immune dysfunction in renal cancer.Frontiers in immunology · 2026Review
- Review
- The prognostic value of adipokine receptors leptinR and adiponectinR1 in obesity-inducible solid tumours.Histology and histopathology · 2025Article
- High-Fat-Diet-Induced Kidney Injury in Rats: The Role of Tart Cherry Supplementation.Antioxidants (Basel, Switzerland) · 2025Article
- Trends in genitourinary tumors: Academic center experience over 16 years.Saudi medical journal · 2025Article
- Is early-life obesity associated with kidney cancer in adulthood?-insights from genetic studies.Translational andrology and urology · 2025Article
- Article
- Association of body mass index with clinicopathological features among patients with clear cell renal cell carcinoma treated with surgery: a retrospective study.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Obesity, defined by body mass index (BMI), is an established risk factor for specific renal cell carcinoma (RCC) subtypes such as clear cell RCC, the most common RCC histology. Many studies have identified an association between obesity and improved survival after diagnosis of RCC, a potential "obesity paradox." Clinically, there is uncertainty whether improved outcomes observed after diagnosis are driven by stage, type of treatment received, or artifacts of longitudinal changes in weight and body composition. The biological mechanisms underlying obesity's influence on RCC are not fully established, but multiomic and mechanistic studies suggest an impact on tumor metabolism, particularly fatty acid metabolism, angiogenesis, and peritumoral inflammation, which are known to be key biological hallmarks of clear cell RCC. Conversely, high-intensity exercise associated with increased muscle mass may be a risk factor for renal medullary carcinoma, a rare RCC subtype that predominantly occurs in individuals with sickle hemoglobinopathies. Herein, we highlight methodologic challenges associated with studying the influence of obesity on RCC and review the clinical evidence and potential underlying mechanisms associating RCC with BMI and body composition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.